Rhumbline Advisers Lowers Stock Position in Anika Therapeutics Inc. $ANIK

Rhumbline Advisers trimmed its position in Anika Therapeutics Inc. (NASDAQ:ANIK) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,111 shares of the biotechnology company’s stock after selling 1,136 shares during the period. Rhumbline Advisers owned approximately 0.15% of Anika Therapeutics worth $317,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ANIK. GAMMA Investing LLC raised its stake in shares of Anika Therapeutics by 4,714.3% during the 1st quarter. GAMMA Investing LLC now owns 6,403 shares of the biotechnology company’s stock worth $96,000 after buying an additional 6,270 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Anika Therapeutics during the 4th quarter worth about $137,000. Cetera Investment Advisers purchased a new stake in shares of Anika Therapeutics during the 1st quarter worth about $152,000. AQR Capital Management LLC acquired a new position in Anika Therapeutics during the 1st quarter worth approximately $181,000. Finally, Squarepoint Ops LLC acquired a new position in Anika Therapeutics during the 4th quarter worth approximately $212,000. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Barrington Research reissued an “outperform” rating and set a $15.00 price target on shares of Anika Therapeutics in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat.com, Anika Therapeutics currently has a consensus rating of “Strong Buy” and a consensus target price of $18.00.

Anika Therapeutics Trading Down 0.5%

Shares of Anika Therapeutics stock opened at $9.07 on Thursday. Anika Therapeutics Inc. has a 1 year low of $7.87 and a 1 year high of $25.65. The stock has a 50-day moving average price of $9.23 and a 200 day moving average price of $11.68. The company has a market cap of $130.79 million, a P/E ratio of -2.19 and a beta of 0.63.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.